BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s shares gained 14.10% to $11.41. Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (BDSI) was interviewed on Bloomberg TV, TheStreet.com and Business News Network on June 11 regarding BUNAVAIL, BDSI’s product for the maintenance treatment of opioid dependence that recently received approval from the U.S. Food and Drug Administration. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), weekly performance is 27.09%. On last trading day company shares ended up $12.29. Analysts mean target price for the company is $15.50. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), distance from 50-day simple moving average (SMA50) is 40.16%.
On June 07, 2014, CytRx Corporation (NASDAQ:CYTR), recently announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas — significantly increasing progression-free survival at six months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. CytRx Corporation (NASDAQ:CYTR), advanced 5.78% in last trading session and ended the day on $5.31. CYTR, return on assets is -68.30%. CytRx Corporation (NASDAQ:CYTR), quarterly performance is 27.34%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), announced that NASDAQ has halted trading of the company’s common stock. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), shares moved up 9.23% in last trading session and was closed at $4.22, while trading in range of $3.80 – 4.65. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), year to date (YTD) performance is -20.90%.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO), reported significantly positive results in its Phase I/II clinical trial involving DCVax-Direct to treat various kinds of inoperable solid tumors. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), ended the last trading day at $7.19. Company weekly volatility is calculated as 9.38% and price to cash ratio as 22.23. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), showed a positive weekly performance of 25.92%.
ImmunoGen, Inc. (NASDAQ:IMGN), has earned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, Analyst Ratings News reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.78. ImmunoGen, Inc. (NASDAQ:IMGN), weekly performance is 10.18%. On last trading day company shares ended up $13.20. Analysts mean target price for the company is $17.05. ImmunoGen, Inc. (NASDAQ:IMGN), distance from 50-day simple moving average (SMA50) is 5.69%.